Wockhardt Peer Comparison
NSE: WOCKPHARMA | BSE: 532300
₹2,310.60
₹125.20
(5.73%)
As on 23-Sep-2026 13:24IST
Market cap
₹37,363 Cr
Revenue (TTM)
₹3,564 Cr
P/E Ratio
91.4
P/B Ratio
7.4
Div. Yield
0 %
Edit
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
37,363 | 27,439 | 26,330 | 27,992 | 23,447 |
Revenue (₹ Cr) |
3,564 | 1,936 | 1,462 | 9,205 | 5,632 |
Net Profit (₹ Cr) |
414.00 | 288.22 | 387.35 | -371.81 | 662.35 |
Net Margin (%) |
11.23 | 14.79 | 26.01 | -3.93 | 11.75 |
RoE (%) |
8.38 | 29.77 | 25.18 | -3.85 | 14.34 |
Price to Earnings |
91.35 | 95.20 | 68.17 | -- | 35.40 |
Price-To-Book |
7.42 | 20.44 | 15.26 | 3.50 | 4.78 |
Income Statement (₹ Cr)
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
|
Operating Revenue
|
3,564.00 | 1,935.80 | 1,461.80 | 9,205.28 | 5,632.31 |
|
Total Income
|
3,686.00 | 1,948.58 | 1,489.25 | 9,449.59 | 5,638.56 |
|
Total Expenditure
|
2,792.00 | 1,485.56 | 919.25 | 8,195.15 | 4,354.97 |
|
EBITDA
|
772.00 | 450.24 | 542.56 | 1,010.13 | 1,277.34 |
|
Depreciation
|
226.00 | 50.83 | 37.68 | 857.51 | 306.94 |
|
EBIT
|
546.00 | 399.41 | 504.88 | 152.62 | 970.39 |
|
Interest
|
217.00 | 40.84 | 3.77 | 342.73 | 111.70 |
|
Other Income
|
122.00 | 12.78 | 27.45 | 244.31 | 6.25 |
|
Exceptional Items
|
12.00 | 0.00 | 0.00 | -216.88 | 15.92 |
|
Profit before Tax
|
463.00 | 371.35 | 528.56 | -162.68 | 880.86 |
|
Provision for Tax
|
49.00 | 83.14 | 141.21 | 209.13 | 218.51 |
|
Profit after Tax
|
414.00 | 288.22 | 387.35 | -371.81 | 662.35 |
Liabilities (₹ Cr)
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
4,940.00 | 1,288.82 | 1,653.56 | 8,162.62 | 5,085.00 |
|
Minority Interest
|
-5.00 | 0.00 | -1.13 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
1,712.00 | 202.03 | 42.40 | 5,044.14 | 542.92 |
|
Current Liabilities
|
1,622.00 | 835.87 | 230.82 | 4,758.28 | 2,092.03 |
|
Total Liabilities
|
8,578.00 | 2,326.71 | 1,983.96 | 17,723.32 | 7,682.91 |
Assets (₹ Cr)
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
5,343.00 | 519.60 | 1,026.85 | 10,211.52 | 3,533.26 |
|
Current Assets
|
2,606.00 | 1,681.81 | 881.27 | 7,191.66 | 3,767.65 |
|
Total Assets
|
8,578.00 | 2,326.71 | 1,983.96 | 17,723.32 | 7,682.91 |
|
Total Debt*
|
2,125.00 | 259.37 | 26.49 | 5,495.48 | 1,338.13 |
|
Net Current Assets
|
984.00 | 845.94 | 650.46 | 2,433.38 | 1,675.62 |
|
Contingent Liabilities
|
768.26 | 19.09 | 17.25 | 95.72 | 0.93 |
Cashflow (₹ Cr)
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
390.00 | 205.05 | 292.17 | 1,652.60 | 793.25 |
|
Cash Flow from Investing Activities
|
-241.00 | -409.72 | -265.94 | -826.03 | -773.21 |
|
Cash from Financing Activities
|
-54.00 | 283.07 | 4.10 | -38.98 | 379.29 |
|
Net Cash Inflow / Outflow
|
95.00 | 78.39 | 30.33 | 787.59 | 399.33 |
Ratios
Profitability Ratios
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
|
ROCE (%)
|
6.79 | 29.22 | 32.42 | 1.24 | 15.74 |
|
ROE (%)
|
8.38 | 29.77 | 25.18 | -3.85 | 14.34 |
|
ROA (%)
|
4.94 | 24.77 | 21.93 | -2.21 | 9.48 |
|
EBIT Margin (%)
|
15.32 | 20.63 | 34.54 | 1.66 | 17.23 |
|
Net Margin (%)
|
11.23 | 14.79 | 26.01 | -3.93 | 11.75 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
18.37 | 46.65 | 40.90 | 0.78 | 24.83 |
|
EBIT Growth (%)
|
252.26 | 62.13 | 124.50 | -70.53 | 40.39 |
|
Net Profit Growth (%)
|
377.85 | 89.49 | 104.15 | -1,383.43 | 38.13 |
|
EPS Growth (%)
|
1,001.33 | 78.60 | 42.32 | -484.84 | 34.88 |
|
Book Value Growth (%)
|
13.47 | 144.31 | 26.03 | 0.33 | 27.49 |
Valuation Ratios
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
|
Price / Earnings
|
89.10 | 94.55 | 68.11 | -89.41 | 32.65 |
|
Price / Book Value
|
7.05 | 20.62 | 15.25 | 3.50 | 4.81 |
|
Dividend Yield (%)
|
0.00 | 0.09 | 0.08 | 0.00 | 0.20 |
|
EV/EBITDA
|
47.88 | 61.28 | 48.12 | 31.80 | 18.77 |
|
Market Cap (₹ Cr)
|
19,071.62 | 12,753.19 | 20,944.75 | 18,108.89 | 15,391.88 |
Solvency Ratios
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.31 | 0.11 | 0.02 | 0.53 | 0.06 |
|
Short term debt to equity ratio
|
0.09 | 0.05 | 0.02 | 0.09 | 0.20 |
|
Current Ratio
|
1.61 | 2.01 | 3.82 | 1.51 | 1.80 |
|
Quick Ratio
|
1.06 | 1.14 | 2.82 | 0.87 | 1.00 |
|
Interest Coverage
|
3.13 | 10.09 | 141.16 | 0.53 | 8.89 |
Operating Efficiency Ratios
| Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | Granules India | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.50 | 26.28 | 24.80 | 23.44 | 16.15 |
|
Asset Turnover
|
0.43 | 1.66 | 0.83 | 0.55 | 0.81 |
|
Receivable days
|
58.75 | 40.13 | 88.98 | 78.20 | 33.72 |
|
Inventory Days
|
75.82 | 60.29 | 56.04 | 93.30 | 54.92 |
|
Payable days
|
186.21 | 232.47 | 99.95 | 226.14 | 136.11 |
|
Cash Conversion Cycle
|
-51.64 | -132.04 | 45.07 | -54.64 | -47.47 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
